newsfilter
← Earnings
Earnings Releases·

Pulmatrix — Third Quarter 2026 Earnings Summary

Pulmatrix, Inc. announced its third-quarter 2026 financial results and confirmed that its merger with Eos SENOLYTIX is expected to close by the end of the year following SEC effectiveness and stockholder approval. The company reported total cash and cash equivalents of $1.4 million as of September 30, 2026, while general and administrative expenses rose to $1.2 million due to merger-related activities. Pulmatrix continues to seek to out-license or monetize its clinical assets, including PUR1900, PUR3100, and PUR1800, while clinical development remains on hold pending these strategic moves.

Company
PULMATRIX INC
Sector
Healthcare
Industry
Biotechnology